Altimmune reports Q2 2025 net loss of $22.1M; positive pemvidutide MASH data reinforces differentiation

Altimmune, Inc.

2025-Q2 EPS reported -$0.53 vs consensus -$0.33 ▼ miss (-62.5%)

Cash and investments $183.1M (up 39% from Dec 2024); net loss $22.1M ($0.27/sh) vs $24.6M ($0.35) Q2 2024.
Pemvidutide achieved up to 59.1% MASH resolution without worsening fibrosis, up to 34.5% fibrosis improvement, and up to 6.2% weight loss at 24 weeks.
New cT1 imaging data shows mean decreases of 145-148 ms (p<0.001), potentially class-leading in MASH trials.
End-of-Phase 2 FDA meeting targeted for Q4 2025; full 48-week data expected Q4.
Jerry Durso appointed Chairman; Mitchel Sayare remains director as part of board succession.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.